Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


29.01.2024

1 BJU Int
1 BMC Urol
7 Br J Radiol
1 Cancer
1 Cancer Lett
1 Curr Treat Options Oncol
3 Eur Urol
1 Int J Urol
2 J Clin Oncol
1 JAMA
1 Mod Pathol
2 Oncogene
1 Prostate
1 Urol Int


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BJU Int

  1. SANCHEZ-SALAS R
    Candid choices: optimising patient selection in prostate cancer focal therapy.
    BJU Int. 2024 Jan 20. doi: 10.1111/bju.16270.
    PubMed        


    BMC Urol

  2. ZHANG H, Li T, Jia Y
    Association of estimated glomerular filtration rate with prostate cancer risk in a cross-ethnic population: a Mendelian randomization study.
    BMC Urol. 2024;24:18.
    PubMed         Abstract available


    Br J Radiol

  3. RAJENDRAN I, Lee KL, Thavaraja L, Barrett T, et al
    Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making.
    Br J Radiol. 2024;97:113-119.
    PubMed         Abstract available

  4. MURAKAMI Y, Kawahara D, Soyano T, Kozuka T, et al
    Dosiomics for intensity-modulated radiotherapy in patients with prostate cancer: survival analysis stratified by baseline prostate-specific antigen and Gleason grade group in a 2-institutional retrospective study.
    Br J Radiol. 2024;97:142-149.
    PubMed         Abstract available

  5. AGGARWAL P, Krishna Kumar RG, Das CJ, Kubihal V, et al
    Role of non-contrast CT component of prostate-specific membrane antigen PET/CT scan in the detection of peripheral zone prostate cancer.
    Br J Radiol. 2024;97:195-200.
    PubMed         Abstract available

  6. WINTER JD, Reddy V, Li W, Craig T, et al
    Impact of technological advances in treatment planning, image guidance, and treatment delivery on target margin design for prostate cancer radiotherapy: an updated review.
    Br J Radiol. 2024;97:31-40.
    PubMed         Abstract available

  7. ALI I, Rezk M, Hamouda D, Talaat O, et al
    Clinical value of 18F-PSMA-1007 PET/MRI in primary staging of patients with intermediate to high risk prostate cancer.
    Br J Radiol. 2024 Jan 23:tqae021. doi: 10.1093.
    PubMed         Abstract available

  8. GIACOMETTI V, Grey AC, McCann AJ, Prise KM, et al
    An objective measure of response on whole-body MRI in metastatic hormone sensitive prostate cancer treated with androgen deprivation therapy, external beam radiotherapy, and radium-223.
    Br J Radiol. 2024 Jan 24:tqae005. doi: 10.1093.
    PubMed         Abstract available

  9. MUKHERJEE S, Papadopoulos D, Chari N, Ellis D, et al
    High-grade prostate cancer demonstrates preferential growth in the cranio-caudal axis and provides discrimination of disease grade in an MRI parametric model.
    Br J Radiol. 2024 Jan 4:tqad066. doi: 10.1093.
    PubMed         Abstract available


    Cancer

  10. XU J, Bock CH, Janisse J, Woo J, et al
    Determinants of active surveillance uptake in a diverse population-based cohort of men with low-risk prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS).
    Cancer. 2024 Jan 22. doi: 10.1002/cncr.35190.
    PubMed         Abstract available


    Cancer Lett

  11. SAEZ-MARTINEZ P, Porcel-Pastrana F, Montero-Hidalgo AJ, Lozano de la Haba S, et al
    Dysregulation of RNA-Exosome machinery is directly linked to major cancer hallmarks in prostate cancer: Oncogenic role of PABPN1.
    Cancer Lett. 2024 Jan 18:216604. doi: 10.1016/j.canlet.2023.216604.
    PubMed         Abstract available


    Curr Treat Options Oncol

  12. WEINER AB, Agrawal R, Valle LF, Sonni I, et al
    Impact of PSMA PET on Prostate Cancer Management.
    Curr Treat Options Oncol. 2024 Jan 25. doi: 10.1007/s11864-024-01181.
    PubMed         Abstract available


    Eur Urol

  13. MIAN BM
    Prostate Biopsy: Hyperbole and Misrepresentation Versus Scientific Evidence and Equipoise.
    Eur Urol. 2024;85:99-100.
    PubMed         Abstract available

  14. PREISSER F, Abrams-Pompe RS, Stelwagen PJ, Bohmer D, et al
    European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter Study.
    Eur Urol. 2024;85:164-170.
    PubMed         Abstract available

  15. DEIVASIGAMANI S, Kotamarti S, Gupta RT, Polascik TJ, et al
    Re: Low Cancer Yield in PI-RADS 3 Upgraded to 4 by Dynamic Contrast-enhanced MRI: Is It Time To Reconsider Scoring Categorization?
    Eur Urol. 2024;85:180-181.
    PubMed        


    Int J Urol

  16. MORI K
    Editorial Comment from Dr Mori to Association between antibiotic use and subsequent risk of prostate cancer: A retrospective cohort study in South Korea.
    Int J Urol. 2024 Jan 24. doi: 10.1111/iju.15402.
    PubMed        


    J Clin Oncol

  17. CHILDS DS, Orme JJ, Ravi P
    Delaying Prostate-Specific Antigen Progression in Biochemically Recurrent Prostate Cancer: Is It Clinically Meaningful?
    J Clin Oncol. 2024 Jan 23:JCO2302410. doi: 10.1200/JCO.23.02410.
    PubMed        

  18. AGGARWAL R, Heller G, Hillman DW, Xiao H, et al
    PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).
    J Clin Oncol. 2024 Jan 23:JCO2301157. doi: 10.1200/JCO.23.01157.
    PubMed         Abstract available


    JAMA

  19. AL HUSSEIN AL AWAMLH B, Wallis CJD, Penson DF, Huang LC, et al
    Functional Outcomes After Localized Prostate Cancer Treatment.
    JAMA. 2024;331:302-317.
    PubMed         Abstract available


    Mod Pathol

  20. MIYAMOTO H, Teramoto Y, Numbere N, Wang Y, et al
    Prostate cancer risk stratification by simple scoring of the current pT3 lesions: A proposal for a new pathologic T-staging system.
    Mod Pathol. 2024 Jan 22:100429. doi: 10.1016/j.modpat.2024.100429.
    PubMed         Abstract available


    Oncogene

  21. CHAO Y, Chen Y, Zheng W, Demanelis K, et al
    Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer.
    Oncogene. 2024 Jan 25. doi: 10.1038/s41388-024-02939.
    PubMed         Abstract available

  22. RODRIGUEZ TIRADO C, Wang C, Li X, Deng S, et al
    UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance.
    Oncogene. 2024;43:265-280.
    PubMed         Abstract available


    Prostate

  23. HUANG H, Liu Z, Ma Y, Shao Y, et al
    Based on PI-RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4-20 ng/mL.
    Prostate. 2024;84:376-388.
    PubMed         Abstract available


    Urol Int

  24. RIEDEL A, Michael M, Grunberg J, Mehralivand S, et al
    The role of multiparametric MRI (mpMRI) in the prediction of adverse prostate cancer pathology in radical prostatectomy specimen.
    Urol Int. 2024 Jan 19. doi: 10.1159/000536256.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.